Investor Relations

Company Information

MiNK Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class invariant natural killer T (iNKT) cell therapies to transform the lives of patients with cancer.
Press Releases
May 10, 2022
Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022 GMP manufacturing launch in 1H 2022 with target 10,000 doses/yr BCMA-CAR-iNKT and stromal-CAR-iNKT preclinical results 2H 2022 Ended First Quarter with $34.7M in cash with a projected 2022 cash burn of

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Form Description Filing date View
DRS

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

View HTML
UPLOAD

UPLOAD

View HTML
DRS/A

Amendment to a previously filed DRS

View HTML
UPLOAD

UPLOAD

View HTML

Data provided by Kaleidoscope.